First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

Journal:

The Lancet Oncology

Published:

2025-10-02

DOI:

10.1016/s1470-2045(25)00409-7

Affiliations:

33

Authors:

46

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	5.500000	0.12
Abramson Cancer Center, Penn, United States of America (USA)	4.000000	0.09
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)	3.000000	0.07
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	3.000000	0.07
Institute Gustave-Roussy (IGR), France	3.000000	0.07
The University of Texas MD Anderson Cancer Center, United States of America (USA)	3.000000	0.07
University of Bologna (UNIBO), Italy	2.500000	0.05
Yale University, United States of America (USA)	2.000000	0.04
IRCCS Regina Elena National Cancer Institute (IRE), Italy	2.000000	0.04
Massachusetts General Hospital (MGH), United States of America (USA)	2.000000	0.04
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	2.000000	0.04
Sant'Orsola Malpighi Hospital, Italy	2.000000	0.04
Henry Ford Health System (HFHS), United States of America (USA)	2.000000	0.04
University Hospital "Santa Maria della Misericordia", Italy	2.000000	0.04
San Raffaele Scientific Institute, Italy	1.500000	0.03
The University of Chicago (UChicago), United States of America (USA)	1.500000	0.03
Harvard University, United States of America (USA)	1.000000	0.02
University Polyclinic, Campus Bio-Medico University, Italy	1.000000	0.02
Beneficência Portuguesa de São Paul, Brazil	1.000000	0.02
Vita-Salute San Raffaele University (UniSR), Italy	0.500000	0.01
Oregon Health and Science University (OHSU), United States of America (USA)	0.500000	0.01
Campus Bio-Medico University, Italy	0.500000	0.01
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy	0.500000	0.01

Interested in Oncology and Carcinogenesis?